Latest Insider Transactions at I Teos Therapeutics, Inc. (ITOS)
This section provides a real-time view of insider transactions for I Teos Therapeutics, Inc. (ITOS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of iTeos Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of iTeos Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2021
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,248
-5.88%
|
$230,944
$28.17 P/Share
|
|
Aug 25
2021
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
861
-0.61%
|
$24,108
$28.0 P/Share
|
|
Aug 24
2021
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
225
-0.16%
|
$6,300
$28.26 P/Share
|
|
Aug 23
2021
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,499
-5.04%
|
$209,972
$28.06 P/Share
|
|
Jul 30
2021
|
Matthew Call Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
53,672
+50.0%
|
$107,344
$2.95 P/Share
|
|
Jun 16
2021
|
Matthew Gall Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$130,000
$26.09 P/Share
|
|
Jun 14
2021
|
Michel Detheux Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,000
-8.33%
|
$812,000
$28.82 P/Share
|
|
Jun 08
2021
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,927
-100.0%
|
$158,540
$20.0 P/Share
|
|
Jun 08
2021
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,927
+50.0%
|
$31,708
$4.23 P/Share
|
|
Jun 02
2021
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
323
-100.0%
|
$6,460
$20.0 P/Share
|
|
Jun 02
2021
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
323
+50.0%
|
$1,292
$4.23 P/Share
|
|
Jun 01
2021
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,604
-100.0%
|
$152,080
$20.18 P/Share
|
|
Jun 01
2021
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,604
+50.0%
|
$30,416
$4.23 P/Share
|
|
May 24
2021
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,927
-100.0%
|
$166,467
$21.92 P/Share
|
|
May 24
2021
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,927
+50.0%
|
$31,708
$4.23 P/Share
|
|
May 17
2021
|
Yvonne Mc Grath Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,926
-89.67%
|
$198,150
$25.28 P/Share
|
|
May 17
2021
|
Yvonne Mc Grath Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,926
+50.0%
|
$31,704
$4.23 P/Share
|
|
Apr 09
2021
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
119
-0.0%
|
$3,451
$29.99 P/Share
|
|
Apr 09
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
119
-0.0%
|
$3,451
$29.99 P/Share
|
|
Apr 09
2021
|
Ansbert Gadicke > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
200
-0.0%
|
$5,800
$29.99 P/Share
|
|
Apr 08
2021
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,304
-0.26%
|
$579,120
$30.76 P/Share
|
|
Apr 08
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,304
-0.26%
|
$579,120
$30.76 P/Share
|
|
Apr 08
2021
|
Ansbert Gadicke > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,304
-0.27%
|
$969,120
$30.76 P/Share
|
|
Apr 07
2021
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
15,670
-0.42%
|
-
|
|
Apr 07
2021
|
Mpm Bioventures 2018, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,783
-0.05%
|
$185,056
$32.92 P/Share
|
|
Apr 07
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
15,670
-0.42%
|
-
|
|
Apr 07
2021
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,783
-0.05%
|
$185,056
$32.92 P/Share
|
|
Apr 07
2021
|
Ansbert Gadicke > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
15,670
-0.26%
|
-
|
|
Apr 07
2021
|
Ansbert Gadicke > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,678
-0.05%
|
$309,696
$32.92 P/Share
|
|
Apr 01
2021
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
421,207
+27.0%
|
$14,321,038
$34.18 P/Share
|
|
Jul 28
2020
|
Ansbert Gadicke > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
320,000
+4.45%
|
$6,080,000
$19.0 P/Share
|
|
Jul 28
2020
|
Ansbert Gadicke > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,742,220
+38.33%
|
-
|
|
Jul 28
2020
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,425,000
+24.39%
|
$27,075,000
$19.0 P/Share
|
|
Jul 28
2020
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,992,259
+50.0%
|
-
|
|
Jul 28
2020
|
Boxer Capital, LLC |
BUY
Open market or private purchase
|
Direct |
1,425,000
+24.49%
|
$27,075,000
$19.0 P/Share
|
|
Jul 28
2020
|
Boxer Capital, LLC |
BUY
Conversion of derivative security
|
Direct |
2,992,259
+50.0%
|
-
|